Compass Therapeutics (CMPX) Payables (2018 - 2026)

Compass Therapeutics has reported Payables for 9 years, with the latest figure at $906000.0 in Q1 2026.

• Quarterly Payables fell 42.55% year-over-year to $906000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $906000.0 (down 42.55% YoY) and the FY2025 annual result came in at $1.6 million, down 29.52% from the prior year.
• Payables declined to $906000.0 in Q1 2026 per CMPX's latest filing, from $1.6 million in the prior quarter.
• Over five years, Payables peaked at $6.5 million in Q2 2022 and troughed at $257000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $1.6 million in 2025 frame the typical range for Payables.
• The widest YoY moves for Payables: up 337.74% in 2023, down 88.92% in 2023.
• Over 5 years, Payables stood at $3.4 million in 2022, then climbed by 20.93% to $4.1 million in 2023, then slumped by 45.01% to $2.2 million in 2024, then decreased by 29.52% to $1.6 million in 2025, then tumbled by 42.84% to $906000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $906000.0, $1.6 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.